CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
Aged
Aged, 80 and over
Animals
Biomarkers, Tumor
Carcinoma, Pancreatic Ductal
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Survival
Disease Models, Animal
Disease Progression
Extracellular Signal-Regulated MAP Kinases
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Liver Neoplasms
/ secondary
Male
Mice
Middle Aged
Pancreatic Neoplasms
/ genetics
Prognosis
Proto-Oncogene Proteins c-myc
/ metabolism
RNA Interference
RNA, Small Interfering
/ genetics
Receptors, Thrombopoietin
/ genetics
Signal Transduction
Xenograft Model Antitumor Assays
CD110
Liver metastasis
Pancreatic cancer
TPO
Transendothelial migration
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
29
11
2018
accepted:
08
02
2019
pubmed:
17
2
2019
medline:
7
5
2019
entrez:
17
2
2019
Statut:
ppublish
Résumé
This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin-CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK-MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.
Identifiants
pubmed: 30770989
doi: 10.1007/s00432-019-02860-z
pii: 10.1007/s00432-019-02860-z
doi:
Substances chimiques
Biomarkers, Tumor
0
Proto-Oncogene Proteins c-myc
0
RNA, Small Interfering
0
Receptors, Thrombopoietin
0
MPL protein, human
143641-95-6
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1164Références
Blood. 1999 Aug 15;94(4):1273-82
pubmed: 10438715
Genes Dev. 2000 Oct 1;14(19):2501-14
pubmed: 11018017
Cancer Res. 2004 Oct 1;64(19):6950-6
pubmed: 15466186
Cancer Res. 2005 Nov 1;65(21):9891-8
pubmed: 16267013
J Clin Invest. 2005 Dec;115(12):3339-47
pubmed: 16322778
Cell Signal. 2006 Aug;18(8):1212-8
pubmed: 16380230
Cancer. 2006 Apr 1;106(7):1624-33
pubmed: 16518827
N Engl J Med. 2006 May 11;354(19):2034-45
pubmed: 16687716
Neoplasia. 2006 Apr;8(4):290-301
pubmed: 16756721
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Genes Dev. 2006 Aug 1;20(15):2096-109
pubmed: 16847353
Nat Med. 2006 Aug;12(8):895-904
pubmed: 16892035
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6
pubmed: 17114293
Cancer. 2007 Dec 1;110(11):2484-92
pubmed: 17941009
Biochem Biophys Res Commun. 2009 May 29;383(2):172-7
pubmed: 19341705
J Cell Mol Med. 2009 Sep;13(9B):4002-13
pubmed: 19426156
J Immunol. 2009 Sep 1;183(5):3204-11
pubmed: 19641136
Cancer. 2010 Jul 15;116(14):3357-68
pubmed: 20564084
Cancer Res. 2010 Jul 15;70(14):5649-69
pubmed: 20610625
PLoS Biol. 2010 Sep 07;8(9):null
pubmed: 20838657
Oncogene. 2011 Mar 24;30(12):1449-59
pubmed: 21102519
Cancer Res. 2011 Feb 1;71(3):925-36
pubmed: 21266350
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Cell. 2011 Jul 8;146(1):148-63
pubmed: 21729786
PLoS One. 2012;7(1):e30046
pubmed: 22253872
Cancer Res. 2012 May 15;72(10):2622-33
pubmed: 22461507
J Cell Biol. 2012 Nov 12;199(4):653-68
pubmed: 23148235
J Exp Med. 2013 Mar 11;210(3):563-79
pubmed: 23401487
Cancer Res. 2013 Mar 15;73(6):1821-30
pubmed: 23467612
Cancer Discov. 2013 Jul;3(7):742-50
pubmed: 23614898
Gastroenterology. 2013 Sep;145(3):636-46.e5
pubmed: 23747337
Oncogene. 2014 Jul 10;33(28):3668-76
pubmed: 23995792
Pathol Oncol Res. 2014 Apr;20(2):309-17
pubmed: 24085601
Nat Rev Cancer. 2013 Dec;13(12):858-70
pubmed: 24263189
Br J Haematol. 2014 Apr;165(2):259-68
pubmed: 24499199
Blood. 2014 Sep 25;124(13):2104-15
pubmed: 25143485
Blood. 2014 Dec 18;124(26):3956-63
pubmed: 25339357
Nat Commun. 2015 Apr 30;6:6993
pubmed: 25925867
Cell Stem Cell. 2015 Jul 2;17(1):47-59
pubmed: 26140605
Mol Carcinog. 2016 Nov;55(11):1560-1572
pubmed: 26373617
Cancer Cell. 2016 Jan 11;29(1):75-89
pubmed: 26725216
Int J Oncol. 2016 Apr;48(4):1688-700
pubmed: 26892887
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
J Mol Cell Biol. 2016 Dec;8(6):553-555
pubmed: 27282404
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641
pubmed: 27956436
Oncogene. 2017 Jul 27;36(30):4336-4348
pubmed: 28368414
Cell Death Dis. 2017 Oct 26;8(10):e3147
pubmed: 29072694
J Gastrointest Oncol. 2018 Feb;9(1):111-125
pubmed: 29564177
Cancer Cell. 2018 Nov 12;34(5):807-822.e7
pubmed: 30423298
Cell. 1994 Jul 1;77(7):1117-24
pubmed: 8020099
Nature. 1994 Jun 16;369(6481):565-8
pubmed: 8202158
Mol Cell Biol. 1997 Sep;17(9):4991-5000
pubmed: 9271377
J Exp Med. 1997 Dec 15;186(12):1947-55
pubmed: 9396763